References
Ambrosini G, Adida C, Altieri DC . A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917–921.
Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000; 60: 4845–4849.
Andersen MH, Pedersen LO, Becker JC, Straten TP . Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 2001; 61: 869–872.
Andersen MH, Pedersen L, Capeller B, Brocker EB, Becker JC, Strahten TP . Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001; 61: 5964–5968.
Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, Straten PT et al. Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther 2004; 3: 4–10.
Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kuhl-Burmeister R et al. Induction of cytotoxic T lymphocytes against hematologic neoplasms by survivin RNA-transfected dendritic cells. J Immunol 2003; 170: 5391–5397.
Schmidt SM, Schlag K, Müller MR, Weck MM, Appel S, Kanz L et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003; 102: 571–576.
Acknowledgements
This study was supported by the German José Carreras Leukemia fund (DJCLS R03/07) and in part by the Cancer Society of Hamburg, Germany.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Siegel, S., Steinmann, J., Schmitz, N. et al. Identification of a survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytes. Leukemia 18, 2046–2047 (2004). https://doi.org/10.1038/sj.leu.2403510
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403510
- Springer Nature Limited
This article is cited by
-
Survivin: a unique target for tumor therapy
Cancer Cell International (2016)
-
Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients
Journal of Translational Medicine (2013)
-
Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia
Leukemia (2012)
-
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer
Journal of Translational Medicine (2008)
-
Immunotherapy of myeloid leukaemia
Cancer Immunology, Immunotherapy (2007)